Journal Article Summary
The article examines the pharmacologic properties of levonorgestrel (LNg), a progestational agent used in combination oral contraceptives, and how these properties influence its clinical effects. Understanding the relationship between the dosage of LNg and its effects is important because it can help inform safer and more effective contraceptive options. The study highlights the significance of distinguishing between the contraceptive and androgenic effects of LNg, which can impact patient outcomes and satisfaction with contraceptive methods.
The researchers analyzed clinical trials involving LNg combined with ethinyl estradiol (EE) to assess its effects at contraceptive doses. They found that lower doses of LNg are effective for contraception without triggering androgenic responses, which can lead to side effects like acne. Specifically, the trials showed that using LNg in combination with EE resulted in increased levels of sex hormone-binding globulin and decreased plasma androgen levels, contributing to improvements in conditions like acne. This suggests that the combination formulations are effective in providing contraceptive benefits while minimizing unwanted androgenic effects.
However, the study has limitations, including the potential for variability in individual responses to hormonal contraceptives. It is essential for patients to discuss their specific health needs and any concerns about side effects with their healthcare providers. Understanding the pharmacologic properties of contraceptives can help patients make informed choices, but personal medical history and individual health conditions should always guide contraceptive decisions.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Upton G. V., Corbin A.. The relevance of the pharmacologic properties of a progestational agent to its clinical effects as a combination oral contraceptive.. The Yale Journal of Biology and Medicine 1989. PMID: 2534253. PMCID: PMC2589161.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive --- Perrigo
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive --- Perrigo is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
